

2025 1 Tier Standard - AmeriHealth Caritas VIP Care

2025 Step Therapy Criteria

CURRENT AS OF 01/01/2025

anticonvulsant step therapy

Products Affected

- FYCOMPA SUSPENSION 0.5 MG/ML ORAL
- FYCOMPA TABLET 10 MG ORAL
- FYCOMPA TABLET 12 MG ORAL
- FYCOMPA TABLET 2 MG ORAL
- FYCOMPA TABLET 4 MG ORAL
- FYCOMPA TABLET 6 MG ORAL
- FYCOMPA TABLET 8 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 1000 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 250 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 500 MG ORAL
- SPRITAM TABLET DISINTEGRATING SOLUBLE 750 MG ORAL
- SYMPAZAN FILM 10 MG ORAL
- SYMPAZAN FILM 20 MG ORAL
- SYMPAZAN FILM 5 MG ORAL
- XCOPRI (250 MG DAILY DOSE) TABLET THERAPY PACK 100 & 150 MG ORAL
- XCOPRI (350 MG DAILY DOSE) TABLET THERAPY PACK 150 & 200 MG ORAL
- XCOPRI TABLET 100 MG ORAL
- XCOPRI TABLET 150 MG ORAL
- XCOPRI TABLET 200 MG ORAL
- XCOPRI TABLET 25 MG ORAL
- XCOPRI TABLET 50 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 12.5 MG & 14 X 25 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 150 MG & 14 X200 MG ORAL
- XCOPRI TABLET THERAPY PACK 14 X 50 MG & 14 X100 MG ORAL
- ZONISADE SUSPENSION 100 MG/5ML ORAL

Details

Criteria
Step 1: First line therapy should be a documented trial, failure, or contraindication of two generic anticonvulsants. Step 2: Once two generic anticonvulsants have been tried, failed, or contraindicated patients can receive therapy with Spritam, Sympazan, Xcopri, Fycompa or Zonisade.

antidepressant step therapy

Products Affected

- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of two generic antidepressants. Step 2: Once two generic antidepressants have been tried, failed, or contraindicated patient can receive therapy with Fetzima.
----------	--

brinzolamide step therapy

Products Affected

- *brinzolamide suspension 1 % ophthalmic*

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of formulary dorzolamide or dorzolamide/timolol. Step 2: Once dorzolamide or dorzolamide/timolol has been tried, failed, or contraindicated the patient can receive therapy with brinzolamide.
-----------------	--

febuxostat step therapy

Products Affected

- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of allopurinol tablet. Step 2: Once allopurinol tablet has been tried, failed, or contraindicated patients can receive therapy with Febuxostat.
-----------------	---

netarsudil step therapy

Products Affected

- RHOPRESSA SOLUTION 0.02 %
OPHTHALMIC
- ROCKLATAN SOLUTION 0.02-0.005 %
OPHTHALMIC

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of latanoprost or travoprost. Step 2: Once latanoprost or travoprost has been tried, failed, or contraindicated patients can receive therapy with Rhopressa or Rocklatan.
-----------------	---

ongentys step therapy

Products Affected

- ONGENTYS CAPSULE 25 MG ORAL
- ONGENTYS CAPSULE 50 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of entacapone or carbidopa-levodopa-entacapone. Step 2: Once entacapone or carbidopa-levodopa-entacapone has been tried, failed, or contraindicated patients can receive therapy with Ongentys.
-----------------	---

savella step therapy

Products Affected

- SAVELLA TABLET 100 MG ORAL
- SAVELLA TABLET 12.5 MG ORAL
- SAVELLA TABLET 25 MG ORAL
- SAVELLA TABLET 50 MG ORAL
- SAVELLA TITRATION PACK 12.5 & 25 & 50 MG ORAL

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication to duloxetine or pregabalin. Step 2: Once duloxetine or pregabalin has been tried, failed or contraindicated patients can receive therapy with Savella.
-----------------	---

topical immunomodulators step therapy

Products Affected

- *pimecrolimus cream 1 % external*
- *tacrolimus ointment 0.03 % external*
- *tacrolimus ointment 0.1 % external*

Details

Criteria	Step 1: First line therapy should be a documented trial, failure, or contraindication of two topical corticosteroids. Step 2: Once two topical corticosteroids have been tried, failed, or contraindicated patients can receive therapy with generic pimecrolimus or generic topical tacrolimus.
-----------------	--

urinary incontinence agents step therapy

Products Affected

- *darifenacin hydrobromide er tablet extended release 24 hour 15 mg oral*
- *darifenacin hydrobromide er tablet extended release 24 hour 7.5 mg oral*
- *trospium chloride er capsule extended release 24 hour 60 mg oral*

Details

Criteria	Step 1: First line therapy should be a documented trial, failure or contraindication of 2 of the following: oxybutynin, oxybutynin ER, trospium, tolterodine, tolterodine ER, fesoterodine ER, or solifenacin. Step 2: Once two of the medications listed in Step 1 have been tried, failed, or contraindicated, patients can receive therapy with trospium ER or darifenacin ER
-----------------	---

Index

B

brinzolamide suspension 1 % ophthalmic... 3

D

darifenacin hydrobromide er tablet extended
release 24 hour 15 mg oral..... 9

darifenacin hydrobromide er tablet extended
release 24 hour 7.5 mg oral..... 9

F

febuxostat tablet 40 mg oral..... 4

febuxostat tablet 80 mg oral..... 4

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 120 MG ORAL ... 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 20 MG ORAL 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 40 MG ORAL 2

FETZIMA CAPSULE EXTENDED

RELEASE 24 HOUR 80 MG ORAL 2

FETZIMA TITRATION CAPSULE ER 24

HOUR THERAPY PACK 20 & 40 MG
ORAL..... 2

FYCOMPA SUSPENSION 0.5 MG/ML

ORAL..... 1

FYCOMPA TABLET 10 MG ORAL..... 1

FYCOMPA TABLET 12 MG ORAL..... 1

FYCOMPA TABLET 2 MG ORAL..... 1

FYCOMPA TABLET 4 MG ORAL..... 1

FYCOMPA TABLET 6 MG ORAL..... 1

FYCOMPA TABLET 8 MG ORAL..... 1

O

ONGENTYS CAPSULE 25 MG ORAL.... 6

ONGENTYS CAPSULE 50 MG ORAL.... 6

P

pimecrolimus cream 1 % external..... 8

R

RHOPRESSA SOLUTION 0.02 %

OPHTHALMIC 5

ROCKLATAN SOLUTION 0.02-0.005 %

OPHTHALMIC 5

S

SAVELLA TABLET 100 MG ORAL..... 7

SAVELLA TABLET 12.5 MG ORAL..... 7

SAVELLA TABLET 25 MG ORAL..... 7

SAVELLA TABLET 50 MG ORAL..... 7

SAVELLA TITRATION PACK 12.5 & 25
& 50 MG ORAL 7

SPRITAM TABLET DISINTEGRATING
SOLUBLE 1000 MG ORAL 1

SPRITAM TABLET DISINTEGRATING
SOLUBLE 250 MG ORAL 1

SPRITAM TABLET DISINTEGRATING
SOLUBLE 500 MG ORAL 1

SPRITAM TABLET DISINTEGRATING
SOLUBLE 750 MG ORAL 1

SYMPAZAN FILM 10 MG ORAL..... 1

SYMPAZAN FILM 20 MG ORAL..... 1

SYMPAZAN FILM 5 MG ORAL..... 1

T

tacrolimus ointment 0.03 % external 8

tacrolimus ointment 0.1 % external 8

tropium chloride er capsule extended
release 24 hour 60 mg oral..... 9

X

XCOPRI (250 MG DAILY DOSE)

TABLET THERAPY PACK 100 & 150
MG ORAL 1

XCOPRI (350 MG DAILY DOSE)

TABLET THERAPY PACK 150 & 200
MG ORAL 1

XCOPRI TABLET 100 MG ORAL 1

XCOPRI TABLET 150 MG ORAL 1

XCOPRI TABLET 200 MG ORAL 1

XCOPRI TABLET 25 MG ORAL 1

XCOPRI TABLET 50 MG ORAL 1

XCOPRI TABLET THERAPY PACK 14 X
12.5 MG & 14 X 25 MG ORAL..... 1

XCOPRI TABLET THERAPY PACK 14 X
150 MG & 14 X200 MG ORAL..... 1

XCOPRI TABLET THERAPY PACK 14 X
50 MG & 14 X100 MG ORAL..... 1

Z

ZONISADE SUSPENSION 100 MG/5ML
ORAL..... 1